{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T20:44:06Z","timestamp":1771620246260,"version":"3.50.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1097\/ftd.0b013e318030def0","type":"journal-article","created":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T08:58:32Z","timestamp":1171529912000},"page":"118-121","source":"Crossref","is-referenced-by-count":51,"title":["Population Estimation of the Effects of Cytochrome P450 2C9 and 2C19 Polymorphisms on Phenobarbital Clearance in Japanese"],"prefix":"10.1097","volume":"29","author":[{"given":"Shuji","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takateru","family":"Ishitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210129","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.0013-9580.2004.12704.x","article-title":"Phenobarbital for the treatment of epilepsy in the 21st century: a critical review.","volume":"45","author":"Kwan","year":"2004","journal-title":"Epilepsia"},{"key":"R2-17-20210129","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(05)70254-4","article-title":"Efficacy assessment of phenobarbital in epilepsy: a large community-based intervention trial in rural China.","volume":"5","author":"Wang","year":"2006","journal-title":"Lancet Neurol"},{"issue":"Suppl 4","key":"R4-17-20210129","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.63.10_suppl_4.S3","article-title":"Pharmacogenetics and enzyme induction\/inhibition properties of antiepileptic drugs.","volume":"63","author":"Anderson","year":"2004","journal-title":"Neurology"},{"key":"R5-17-20210129","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s002280050703","article-title":"CYP2C19 polymorphism effect on phenobarbitone: pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics.","volume":"55","author":"Mamiya","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"R6-17-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00007691-200104000-00004","article-title":"P-hydroxylation of phenobarbital: relationship to (s)-mephenytoin hydroxylation (CYP2C19) polymorphism.","volume":"23","author":"Hadama","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R7-17-20210129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/hmg\/2.2.159","article-title":"Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes\/swabs.","volume":"2","author":"Richards","year":"1993","journal-title":"Hum Mol Genet"},{"key":"R8-17-20210129","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00008571-199710000-00011","article-title":"Genetic analysis of CYP2C9 polymorphism in a Japanese population.","volume":"7","author":"Nasu","year":"1997","journal-title":"Pharmacogenetics"},{"key":"R9-17-20210129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0009-9236(96)90214-3","article-title":"Genotyping of S-mephenytoin 4-hydroxylation in an extended Japanese population.","volume":"60","author":"Kubota","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"R10-17-20210129","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.","volume":"269","author":"de Morais","year":"1994","journal-title":"J Biol Chem"},{"key":"R11-17-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","article-title":"Clinical consequences of cytochrome P450 2C9 polymorphisms.","volume":"77","author":"Kirchheiner","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R12-17-20210129","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00008571-199702000-00008","article-title":"Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.","volume":"7","author":"Goldstein","year":"1997","journal-title":"Pharmacogenetics"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318030def0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:34:46Z","timestamp":1620952486000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200702000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318030def0","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}